Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 2
1993 4
1994 6
1995 3
1996 4
1997 2
1998 7
1999 1
2000 3
2001 4
2002 6
2003 3
2004 5
2005 5
2006 5
2007 3
2008 1
2011 2
2012 1
2013 1
2014 1
2015 1
2016 2
2017 5
2018 2
2019 2
2020 3
2021 2
2022 4
2023 1
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. Heinemann V, et al. Among authors: heintges t. Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31. Lancet Oncol. 2014. PMID: 25088940 Clinical Trial.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Miller-Phillips L, Modest DP, Jung A, Kirchner T, Stintzing S. Heinemann V, et al. Among authors: heintges t. Br J Cancer. 2021 Feb;124(3):587-594. doi: 10.1038/s41416-020-01140-9. Epub 2020 Nov 6. Br J Cancer. 2021. PMID: 33154570 Free PMC article. Clinical Trial.
SEN virus infection.
Sagir A, Kirschberg O, Heintges T, Erhardt A, Häussinger D. Sagir A, et al. Among authors: heintges t. Rev Med Virol. 2004 May-Jun;14(3):141-8. doi: 10.1002/rmv.421. Rev Med Virol. 2004. PMID: 15124231 Review.
[HIV-HBV-coinfection--diagnosis and therapy].
Koch S, Göbels K, Oette M, Heintges T, Erhardt A, Häussinger D. Koch S, et al. Among authors: heintges t. Dtsch Med Wochenschr. 2006 Aug 25;131(34-35):1873-7. doi: 10.1055/s-2006-949173. Dtsch Med Wochenschr. 2006. PMID: 16915550 Review. German. No abstract available.
[Antiviral therapy of hepatitis C].
Erhardt A, Petry W, Ebel M, Jablonowski H, Heintges T, Häussinger D. Erhardt A, et al. Among authors: heintges t. Z Gastroenterol. 2000 Mar;38(3):259-69. doi: 10.1055/s-2000-14867. Z Gastroenterol. 2000. PMID: 10768250 Review. German.
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.
Holch JW, Ohnmacht AJ, Stintzing S, Heinrich K, Weiss L, Probst V, Stahler A, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Link H, Höffkes HG, Moehler M, Modest DP, Menden MP, Heinemann V. Holch JW, et al. Among authors: heintges t. Eur J Cancer. 2025 May 2;220:115388. doi: 10.1016/j.ejca.2025.115388. Epub 2025 Mar 25. Eur J Cancer. 2025. PMID: 40179821 Free article. Clinical Trial.
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
Weiss L, Stintzing S, Stahler A, Benedikt Westphalen C, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller CA, Kahl C, Seipelt G, Kullmann F, Heinrich K, Holch JW, Alig A, Jung A, Modest DP, Heinemann V. Weiss L, et al. Among authors: heintges t. Eur J Cancer. 2025 May 15;221:115399. doi: 10.1016/j.ejca.2025.115399. Epub 2025 Apr 4. Eur J Cancer. 2025. PMID: 40222201 Free article. Clinical Trial.
[Update hepatitis D].
Erhardt A, Starke C, Loerke J, Giesecke C, Heintges T, Häussinger D. Erhardt A, et al. Among authors: heintges t. Med Klin (Munich). 2006 Mar 22;101 Suppl 1:127-34. Med Klin (Munich). 2006. PMID: 16802537 German.
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
Battaglin F, O'Neil BH, Stintzing S, Ou FS, Zemla TJ, Niedzwiecki D, Innocenti F, Hochster HS, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Heintges T, Lerchenmüller C, Weiss L, Heinrich K, Goldberg RM, Mayer RJ, Schilsky RL, Blanke CD, Venook AP, Lenz HJ, Heinemann V. Battaglin F, et al. Among authors: heintges t. Eur J Cancer. 2025 Sep 9;227:115694. doi: 10.1016/j.ejca.2025.115694. Epub 2025 Aug 5. Eur J Cancer. 2025. PMID: 40803104 Clinical Trial.
Effects of CCK on pancreatic function and morphology.
Niederau C, Lüthen R, Heintges T. Niederau C, et al. Among authors: heintges t. Ann N Y Acad Sci. 1994 Mar 23;713:180-98. doi: 10.1111/j.1749-6632.1994.tb44065.x. Ann N Y Acad Sci. 1994. PMID: 8185159 Review.
89 results